BCAX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Bicara Therapeutics Inc. Common Stock

NASDAQ | BCAX

18.57

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 13, 2025)

$971.01M

Market Cap

-

P/E Ratio

-4.66

EPS

$28.09

52 Week High

$7.80

52 Week Low

HEALTHCARE

Sector

BCAX Chart

Recent Chart
Price Action

BCAX Technicals

Tags:

BCAX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$56K
Total Revenue $0
Cost Of Revenue $56K
Costof Goods And Services Sold $56K
Operating Income -$82M
Selling General And Administrative $19M
Research And Development $8.2M
Operating Expenses $82M
Investment Income Net -
Net Interest Income $15M
Interest Income $15M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $56K
Income Before Tax -$68M
Income Tax Expense $187K
Interest And Debt Expense -
Net Income From Continuing Operations -$68M
Comprehensive Income Net Of Tax -
Ebit -$68M
Ebitda -$68M
Net Income -$68M

Revenue & Profitability

Earnings Performance

BCAX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $510M
Total Current Assets $503M
Cash And Cash Equivalents At Carrying Value $490M
Cash And Short Term Investments $490M
Inventory -
Current Net Receivables -
Total Non Current Assets $7.5M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $13M
Other Non Current Assets -
Total Liabilities $18M
Total Current Liabilities $18M
Current Accounts Payable $3.9M
Deferred Revenue -
Current Debt -
Short Term Debt $1.2M
Total Non Current Liabilities $131K
Capital Lease Obligations $738K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $738K
Other Current Liabilities $13M
Other Non Current Liabilities -
Total Shareholder Equity $492M
Treasury Stock -
Retained Earnings -$221M
Common Stock $7K
Common Stock Shares Outstanding $54M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$75M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $56K
Capital Expenditures $71K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$9K
Cashflow From Financing $334M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$68M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$56K
Total Revenue $0
Cost Of Revenue $56K
Costof Goods And Services Sold $56K
Operating Income -$82M
Selling General And Administrative $19M
Research And Development $8.2M
Operating Expenses $82M
Investment Income Net -
Net Interest Income $15M
Interest Income $15M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $56K
Income Before Tax -$68M
Income Tax Expense $187K
Interest And Debt Expense -
Net Income From Continuing Operations -$68M
Comprehensive Income Net Of Tax -
Ebit -$68M
Ebitda -$68M
Net Income -$68M

BCAX News

BCAX Profile

Bicara Therapeutics Inc. Common Stock Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Bicara Therapeutics Inc. (BCAX) is a clinical-stage biopharmaceutical company focused on the innovative development of bifunctional therapeutics designed to address solid tumors. Based in Boston, Massachusetts, the company is pioneering a novel approach that combines dual-targeted mechanisms to enhance antitumor efficacy while minimizing systemic toxicity. Bicara's lead candidates are advancing through clinical trials, showcasing promising potential in the competitive oncology landscape, thereby positioning the company as a key player in the next generation of cancer treatments.

VHAI
-25.00%
$0.00
YYAI
-14.74%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+5.36%
$0.50
ELBM
+272.00%
$6.13
PLUG
+10.38%
$3.77
GWH
+170.12%
$11.23
BYND
-46.77%
$1.06
BITF
+23.72%
$5.19
NVDA
+2.99%
$188.64
ASST
-29.09%
$1.10
RGTI
+17.89%
$51.78
SNAP
-7.15%
$7.78
IONZ
-29.05%
$2.41
AXDX
-61.36%
$0.03
DNN
+6.42%
$3.06
NVTS
+22.35%
$10.06
GPUS
-9.16%
$0.43
INTC
+2.21%
$37.17
CAN
+27.44%
$1.38
MP
+8.36%
$78.34
PWM
+12.50%
$1.17
QS
+17.68%
$17.30
NIO
+6.70%
$7.16
QBTS
+18.50%
$39.13
CRML
+42.25%
$21.31
F
+1.05%
$11.53
TLRY
-1.73%
$1.69
TSLA
+3.25%
$426.95
JOBY
+4.29%
$16.98
RMBL
+60.50%
$3.21
SOUN
+9.27%
$18.97
ADD
-25.47%
$0.05
LAES
+11.73%
$6.04
BBD
+1.47%
$3.10
CIFR
+16.14%
$19.71
USAR
+20.65%
$39.34
AMD
+2.20%
$219.64
ETHD
-8.24%
$3.50
ABAT
+37.13%
$9.25
HPE
-7.04%
$24.40
APLD
+8.20%
$36.78
SRM
+53.27%
$10.30
ONDS
+20.11%
$11.07
RXRX
+1.03%
$5.37
INTS
-3.97%
$0.30
UUUU
+18.68%
$24.14
DVLT
-7.63%
$1.75
EOSE
+21.59%
$16.80
EPWK
-10.88%
$0.08
NAK
+19.00%
$2.41
ACHR
+5.47%
$12.62
SOFI
+2.55%
$26.85
RR
+10.38%
$6.53
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
NOK
-1.50%
$5.24
CLF
+5.19%
$13.86
NEHC
-8.12%
$2.60
DFLI
+24.58%
$1.35
WLGS
-5.57%
$0.04
IREN
+10.78%
$66.21
PFE
+0.12%
$24.81
AVGO
+10.50%
$358.74
AAL
+1.87%
$11.73
BTBT
+2.32%
$3.84
KDLY
-7.21%
$0.87
GDXD
-13.41%
$0.73
QUBT
+11.12%
$21.13
ADAP
+3.83%
$0.19
UAMY
+30.87%
$15.98
AMC
+0.68%
$2.95
PLTR
+0.66%
$176.61
ETWO
0.00%
$3.30
NB
+3.56%
$10.76
NAKA
-1.14%
$0.86
MARA
+9.16%
$20.36
BULL
+0.30%
$11.43
PMAX
+74.19%
$4.51
WULF
+4.66%
$14.14
BMNR
+3.59%
$54.35
RIG
+2.59%
$3.16
AFMD
-34.94%
$0.18
CLSK
+0.98%
$19.47
AMZN
+1.92%
$220.53
TMQ
+12.11%
$6.64
NAMM
+27.21%
$4.01
SMR
+15.72%
$45.41
IONQ
+13.69%
$80.32
QSI
+22.03%
$2.03
TMC
+17.38%
$10.43
OPI
-16.97%
$0.20
AAPL
+1.49%
$248.93
HOOD
-0.10%
$138.81
KLG
-9.05%
$13.35
GRYP
-10.38%
$1.38
OKLO
+14.55%
$168.58
VHAI
-25.00%
$0.00
YYAI
-14.74%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+5.36%
$0.50
ELBM
+272.00%
$6.13
PLUG
+10.38%
$3.77
GWH
+170.12%
$11.23
BYND
-46.77%
$1.06
BITF
+23.72%
$5.19
NVDA
+2.99%
$188.64
ASST
-29.09%
$1.10
RGTI
+17.89%
$51.78
SNAP
-7.15%
$7.78
IONZ
-29.05%
$2.41
AXDX
-61.36%
$0.03
DNN
+6.42%
$3.06
NVTS
+22.35%
$10.06
GPUS
-9.16%
$0.43
INTC
+2.21%
$37.17
CAN
+27.44%
$1.38
MP
+8.36%
$78.34
PWM
+12.50%
$1.17
QS
+17.68%
$17.30
NIO
+6.70%
$7.16
QBTS
+18.50%
$39.13
CRML
+42.25%
$21.31
F
+1.05%
$11.53
TLRY
-1.73%
$1.69
TSLA
+3.25%
$426.95
JOBY
+4.29%
$16.98
RMBL
+60.50%
$3.21
SOUN
+9.27%
$18.97
ADD
-25.47%
$0.05
LAES
+11.73%
$6.04
BBD
+1.47%
$3.10
CIFR
+16.14%
$19.71
USAR
+20.65%
$39.34
AMD
+2.20%
$219.64
ETHD
-8.24%
$3.50
ABAT
+37.13%
$9.25
HPE
-7.04%
$24.40
APLD
+8.20%
$36.78
SRM
+53.27%
$10.30
ONDS
+20.11%
$11.07
RXRX
+1.03%
$5.37
INTS
-3.97%
$0.30
UUUU
+18.68%
$24.14
DVLT
-7.63%
$1.75
EOSE
+21.59%
$16.80
EPWK
-10.88%
$0.08
NAK
+19.00%
$2.41
ACHR
+5.47%
$12.62
SOFI
+2.55%
$26.85
RR
+10.38%
$6.53
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
NOK
-1.50%
$5.24
CLF
+5.19%
$13.86
NEHC
-8.12%
$2.60
DFLI
+24.58%
$1.35
WLGS
-5.57%
$0.04
IREN
+10.78%
$66.21
PFE
+0.12%
$24.81
AVGO
+10.50%
$358.74
AAL
+1.87%
$11.73
BTBT
+2.32%
$3.84
KDLY
-7.21%
$0.87
GDXD
-13.41%
$0.73
QUBT
+11.12%
$21.13
ADAP
+3.83%
$0.19
UAMY
+30.87%
$15.98
AMC
+0.68%
$2.95
PLTR
+0.66%
$176.61
ETWO
0.00%
$3.30
NB
+3.56%
$10.76
NAKA
-1.14%
$0.86
MARA
+9.16%
$20.36
BULL
+0.30%
$11.43
PMAX
+74.19%
$4.51
WULF
+4.66%
$14.14
BMNR
+3.59%
$54.35
RIG
+2.59%
$3.16
AFMD
-34.94%
$0.18
CLSK
+0.98%
$19.47
AMZN
+1.92%
$220.53
TMQ
+12.11%
$6.64
NAMM
+27.21%
$4.01
SMR
+15.72%
$45.41
IONQ
+13.69%
$80.32
QSI
+22.03%
$2.03
TMC
+17.38%
$10.43
OPI
-16.97%
$0.20
AAPL
+1.49%
$248.93
HOOD
-0.10%
$138.81
KLG
-9.05%
$13.35
GRYP
-10.38%
$1.38
OKLO
+14.55%
$168.58
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.